Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Javier Garau

Showing results (31-40 of 89) with videos related to

Pageof 9
Sort By:
BMC Infectious Diseases|April 17, 2015
Early response to antibiotic treatment in European patients hospitalized with complicated skin and soft tissue infections: analysis of the REACH studyJavier Garau, Francesco Blasi, Jesús Medina, et al.
The Journal of Antimicrobial Chemotherapy|October 18, 2003
Oral pharmacokinetically enhanced co-amoxiclav 2000/125 mg, twice daily, compared with co-amoxiclav 875/125 mg, three times daily, in the treatment of community-acquired pneumonia in European adultsJavier Garau, Monique Twynholm, Elena Garcia-Mendez, et al.
Antimicrobial Agents and Chemotherapy|April 23, 2008
Systemic expression of cytokine production in patients with severe pneumococcal pneumonia: effects of treatment with a beta-lactam versus a fluoroquinoloneEsther Calbo, Montserrat Alsina, Mónica Rodríguez-Carballeira, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 31, 2002
Hospital-acquired pneumococcal bacteremiaJoan-Josep Canet, Natalia Juan, Mariona Xercavins, et al.
BMC Pulmonary Medicine|March 6, 2014
Resource use by patients hospitalized with community-acquired pneumonia in Europe: analysis of the REACH studyHelmut Ostermann, Javier Garau, Jesús Medina, et al.
The Journal of Antimicrobial Chemotherapy|March 31, 2007
Cost-effectiveness of empirical prescribing of antimicrobials in community-acquired pneumonia in three countries in the presence of resistanceMonique Martin, Sibilia Quilici, Thomas File, et al.
Respiratory Research|April 17, 2013
Current management of patients hospitalized with community-acquired pneumonia across Europe: outcomes from REACHFrancesco Blasi, Javier Garau, Jesús Medina, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|March 1, 2002
Upper respiratory tract infections: etiology, current treatment, and experience with fluoroquinolonesJavier Garau, Beatrix Barry, Jean-Paul Butzler, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|December 6, 2005
[Risk factors and prognostic factors in nosocomial pneumonia outside the intensive care units setting]Bienvenido Barreiro-López, Josep Maria Tricas, Elisabeth Mauri, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|February 7, 2009
[The infectious disease specialty in Europe and America]Jesús Rodríguez-Baño, Julio Arrizabalaga, Juan Berenguer, et al.
Pageof 9

Showing results (31-40 of 89) with videos related to

Sort By:
Pageof 9
BMC Infectious Diseases|April 17, 2015
Early response to antibiotic treatment in European patients hospitalized with complicated skin and soft tissue infections: analysis of the REACH studyJavier Garau, Francesco Blasi, Jesús Medina, et al.
The Journal of Antimicrobial Chemotherapy|October 18, 2003
Oral pharmacokinetically enhanced co-amoxiclav 2000/125 mg, twice daily, compared with co-amoxiclav 875/125 mg, three times daily, in the treatment of community-acquired pneumonia in European adultsJavier Garau, Monique Twynholm, Elena Garcia-Mendez, et al.
Antimicrobial Agents and Chemotherapy|April 23, 2008
Systemic expression of cytokine production in patients with severe pneumococcal pneumonia: effects of treatment with a beta-lactam versus a fluoroquinoloneEsther Calbo, Montserrat Alsina, Mónica Rodríguez-Carballeira, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 31, 2002
Hospital-acquired pneumococcal bacteremiaJoan-Josep Canet, Natalia Juan, Mariona Xercavins, et al.
BMC Pulmonary Medicine|March 6, 2014
Resource use by patients hospitalized with community-acquired pneumonia in Europe: analysis of the REACH studyHelmut Ostermann, Javier Garau, Jesús Medina, et al.
The Journal of Antimicrobial Chemotherapy|March 31, 2007
Cost-effectiveness of empirical prescribing of antimicrobials in community-acquired pneumonia in three countries in the presence of resistanceMonique Martin, Sibilia Quilici, Thomas File, et al.
Respiratory Research|April 17, 2013
Current management of patients hospitalized with community-acquired pneumonia across Europe: outcomes from REACHFrancesco Blasi, Javier Garau, Jesús Medina, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|March 1, 2002
Upper respiratory tract infections: etiology, current treatment, and experience with fluoroquinolonesJavier Garau, Beatrix Barry, Jean-Paul Butzler, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|December 6, 2005
[Risk factors and prognostic factors in nosocomial pneumonia outside the intensive care units setting]Bienvenido Barreiro-López, Josep Maria Tricas, Elisabeth Mauri, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|February 7, 2009
[The infectious disease specialty in Europe and America]Jesús Rodríguez-Baño, Julio Arrizabalaga, Juan Berenguer, et al.
Pageof 9